Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches

被引:34
作者
Hoffer, Laurent [1 ]
Muller, Christophe [2 ]
Roche, Philippe [1 ]
Morelli, Xavier [1 ,2 ]
机构
[1] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,CRCM, Marseille, France
[2] Inst Paoli Calmettes, IPC Drug Discovery, Marseille, France
关键词
hit-to-lead; structure-based drug design; de novo design; hit optimization; medicinal chemistry; library design; fragment optimization; growing; linking; merging; virtual screening; SMALL-MOLECULE INHIBITORS; PROTEIN-LIGAND ENTITIES; DE-NOVO DESIGN; DRUG DESIGN; FRAGMENT; DISCOVERY; DOCKING; EFFICIENT; PROGRAM; GENERATION;
D O I
10.1002/minf.201800059
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
For several decades, hit identification for drug discovery has been facilitated by developments in both fragment-based and high-throughput screening technologies. However, a major bottleneck in drug discovery projects continues to be the optimization of primary hits from screening campaigns in order to derive lead compounds. Computational chemistry or molecular modeling can play an important role during this hit-to-lead (H2L) stage by both suggesting putative optimizations and decreasing the number of compounds to be experimentally synthesized and evaluated. However, it is also crucial to consider the feasibility of organically synthesizing these virtually designed compounds. Furthermore, the generated molecules should have reasonable physicochemical properties and be medicinally relevant. This review focuses on chemistry-driven and structure-based computational methods that can be used to tackle the difficult problem of H2L optimization, with emphasis being placed on the strategy developed in our laboratory.
引用
收藏
页数:9
相关论文
共 85 条
[1]  
Alanine A, 2003, COMB CHEM HIGH T SCR, V6, P51
[2]   Customizable De Novo Design Strategies for DOCK: Application to HIVgp41 and Other Therapeutic Targets [J].
Allen, William J. ;
Fochtman, Brian C. ;
Balius, Trent E. ;
Rizzo, Robert C. .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2017, 38 (30) :2641-2663
[3]   Discovery of a Novel Hsp90 Inhibitor by Fragment Linking [J].
Barker, John J. ;
Barker, Oliver ;
Courtney, Stephen M. ;
Gardiner, Mihaly ;
Hesterkamp, Thomas ;
Ichihara, Osamu ;
Mather, Owen ;
Montalbetti, Christian A. G. N. ;
Mueller, Annett ;
Varasi, Mario ;
Whittaker, Mark ;
Yarnold, Christopher J. .
CHEMMEDCHEM, 2010, 5 (10) :1697-1700
[4]   Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple) [J].
Batiste, Laurent ;
Unzue, Andrea ;
Dolbois, Aymeric ;
Hassler, Fabrice ;
Wang, Xuan ;
Deerain, Nicholas ;
Zhu, Jian ;
Spiliotopoulos, Dimitrios ;
Nevado, Cristina ;
Caflisch, Amedeo .
ACS CENTRAL SCIENCE, 2018, 4 (02) :180-188
[5]   LiGen: A High Performance Workflow for Chemistry Driven de Novo Design [J].
Beccari, Andrea R. ;
Cavazzoni, Carlo ;
Beato, Claudia ;
Costantino, Gabriele .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2013, 53 (06) :1518-1527
[6]  
Bienstock Rachelle J, 2015, Methods Mol Biol, V1289, P119, DOI 10.1007/978-1-4939-2486-8_10
[7]   Hit and lead generation:: Beyond high-throughput screening [J].
Bleicher, KH ;
Böhm, HJ ;
Müller, K ;
Alanine, AI .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (05) :369-378
[8]   THE COMPUTER-PROGRAM LUDI - A NEW METHOD FOR THE DENOVO DESIGN OF ENZYME-INHIBITORS [J].
BOHM, HJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1992, 6 (01) :61-78
[9]   Entropic Contribution to the Linking Coefficient in Fragment Based Drug Design: A Case Study [J].
Borsi, Valentina ;
Calderone, Vito ;
Fragai, Marco ;
Luchinat, Claudio ;
Sarti, Niko .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (10) :4285-4289
[10]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217